Aileen Cohen

2.2k total citations
30 papers, 366 citations indexed

About

Aileen Cohen is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Aileen Cohen has authored 30 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Genetics, 12 papers in Pathology and Forensic Medicine and 7 papers in Hematology. Recurrent topics in Aileen Cohen's work include Chronic Lymphocytic Leukemia Research (28 papers), Lymphoma Diagnosis and Treatment (12 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Aileen Cohen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (28 papers), Lymphoma Diagnosis and Treatment (12 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Aileen Cohen collaborates with scholars based in United States, Australia and China. Aileen Cohen's co-authors include Jane Huang, Constantine S. Tam, Stephan Lanes, Kenneth J. Rothman, Nancy A Dreyer, Alessandra Tedeschi, Jennifer R. Brown, Peter Hillmen, Nancy Tait and David A. Van Echo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Aileen Cohen

30 papers receiving 352 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aileen Cohen United States	11	269	244	125	76	67	30	366
George P. Keogh United States	6	177 0.7×	156 0.6×	73 0.6×	68 0.9×	133 2.0×	10	323
Jaimal Kothari United Kingdom	11	122 0.5×	131 0.5×	146 1.2×	34 0.4×	101 1.5×	35	311
Catia Bigazzi Italy	11	184 0.7×	148 0.6×	181 1.4×	53 0.7×	121 1.8×	16	368
Shenmiao Yang China	7	177 0.7×	150 0.6×	92 0.7×	83 1.1×	63 0.9×	37	296
Gerasimos Pangalis Greece	9	233 0.9×	184 0.8×	108 0.9×	75 1.0×	71 1.1×	21	376
Amber B. Koehler United States	10	290 1.1×	219 0.9×	69 0.6×	82 1.1×	69 1.0×	29	338
Bianca Schuhmacher Germany	6	116 0.4×	110 0.5×	117 0.9×	84 1.1×	85 1.3×	9	316
Florence Broussais‐Guillaumot France	9	95 0.4×	228 0.9×	45 0.4×	55 0.7×	153 2.3×	14	305
Polina Kaplan Poland	6	283 1.1×	228 0.9×	116 0.9×	94 1.2×	59 0.9×	9	331
Efstathios Koulieris Greece	10	106 0.4×	85 0.3×	141 1.1×	46 0.6×	103 1.5×	24	262

Countries citing papers authored by Aileen Cohen

Since Specialization

Citations

This map shows the geographic impact of Aileen Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aileen Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aileen Cohen more than expected).

Fields of papers citing papers by Aileen Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aileen Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aileen Cohen. The network helps show where Aileen Cohen may publish in the future.

Co-authorship network of co-authors of Aileen Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Aileen Cohen. A scholar is included among the top collaborators of Aileen Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aileen Cohen. Aileen Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moslehi, Javid J., Richard R. Furman, Constantine S. Tam, et al.. (2024). Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib. Blood Advances. 8(10). 2478–2490. 8 indexed citations

Tam, Constantine S., Mazyar Shadman, Jeff P. Sharman, et al.. (2023). PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES. HemaSphere. 7(S3). e70124b5–e70124b5. 1 indexed citations

Castillo, Jorge J., Edwin Kingsley, Mohit Narang, et al.. (2023). Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States. SHILAP Revista de lepidopterología. 4(1). 301–304. 3 indexed citations

Cohen, Aileen, et al.. (2023). A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers. Clinical Pharmacology in Drug Development. 12(8). 832–838. 2 indexed citations

Tam, Constantine S., Javier Muñoz, Gavin Cull, et al.. (2023). Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia. HemaSphere. 7(4). e870–e870. 15 indexed citations

Chanan‐Khan, Asher, et al.. (2022). Efficacy of first-line treatment for chronic lymphocytic leukemia: A Bayesian network meta-analysis.. Journal of Clinical Oncology. 40(16_suppl). e19526–e19526. 1 indexed citations

Shadman, Mazyar, Ian W. Flinn, Edwin Kingsley, et al.. (2022). PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES. HemaSphere. 6. 1769–1770. 1 indexed citations

Shadman, Mazyar, Ian W. Flinn, Edwin Kingsley, et al.. (2022). Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies. Blood. 140(Supplement 1). 3655–3657. 2 indexed citations

Tam, Constantine S., Ramón García‐Sánz, Stephen Opat, et al.. (2022). ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 40(16_suppl). 7521–7521. 14 indexed citations

10.

Tedeschi, Alessandra, Emmanuelle Ferrant, Ian W. Flinn, et al.. (2021). Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial. Blood. 138(Supplement 1). 67–67. 23 indexed citations

11.

Castillo, Jorge J., Yu Wang, Aileen Cohen, et al.. (2021). Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): Matching-adjusted indirect comparisons.. Journal of Clinical Oncology. 39(15_suppl). 7559–7559. 1 indexed citations

12.

García‐Sánz, Ramón, Meletios Α. Dimopoulos, Marek Trněný, et al.. (2020). Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88^WT) Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 38(15_suppl). e20056–e20056. 6 indexed citations

13.

Shadman, Mazyar, Jeff P. Sharman, Moshe Levy, et al.. (2020). Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib. Blood. 136(Supplement 1). 51–52. 3 indexed citations

14.

Hillmen, Peter, Jennifer R. Brown, Barbara Eichhorst, et al.. (2020). ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncology. 16(10). 517–523. 56 indexed citations

15.

Tam, Constantine S., Ian W. Flinn, Alessandra Tedeschi, et al.. (2020). Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial. Blood. 136(Supplement 1). 24–25. 2 indexed citations

16.

Tam, Constantine S., Stephen Opat, Shirley D’Sa, et al.. (2020). ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 38(15_suppl). 8007–8007. 11 indexed citations

17.

Dimopoulos, Meletios Α., Stephen Opat, Gavin Cull, et al.. (2019). PF487 MAJOR RESPONSES IN MYD88 WILDTYPE (MYD88WT) WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111). HemaSphere. 3(S1). 196–196. 7 indexed citations

18.

Hillmen, Peter, Jennifer R. Brown, Brad S. Kahl, et al.. (2018). Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).. Journal of Clinical Oncology. 36(15_suppl). TPS7581–TPS7581. 5 indexed citations

19.

Cher, Lawrence, James Griffiths, Aileen Cohen, et al.. (2018). Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome. HemaSphere. 2(6). e155–e155. 24 indexed citations

20.

Egorin, Merrill J., et al.. (1988). Phase I and Pharmacokinetic Trial of Carboplatin in Refractory Adult Leukemia. JNCI Journal of the National Cancer Institute. 80(2). 131–135. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact